Assays' Gammacoat "one-step," and Corning's Immophase "single-step").In subjects with albumin deficiency per so, Amerlexand Coat-A-Countresultsfor free thyroxinwere not significantlydifferent from normal, whereas free thyroxin values by Gammacoat and Immophase assays were lower than that of the control.Furthermore,in the albumin-deficient group,the mean amountof thyroxinassociatedwith antisera in each assay was significantlyhigherthan that ofthe control and correlated well with the degree of decrease in free thyroxin. I conclude that subnormal results for thyroxin by analogassays, in euthyroidpatientswith albumindeficiency, is a functionof the specificassays and is not a characteristic of analog assays per Se. In addition,the studysuggeststhat albumin deficiency alters the distributionbetween thyroxin and its binders in all four analog assays, but only in the Gammacoat and Immophasemethodsis this alterationsufficientlylarge as to distortassay results.
addition, Stockigt et al. (9) found that in hereditary analbuminemia, FF4 was almost undetectable by two analog assays. From these observations, many researchers (5,6,10) have suggested that the low FF4 results obtained by analog assays in the third trimester of pregnancy and in clinically euthyroid patients with severe nonthyroidal illnesses (NTI) could be an artefact of methodology related to the low concentrations of albumin in the serum of these patients.
No previous study, however, has directly examined the effect of albumin on results of four different FF4 analog assays at the actual concentrations of albumin that are encountered during late pregnancy and in NTI.
Materials and Methods

Procedures
All sera were assayed for FF4, T4, triiodothyromne (T3) uptake, FF4 index, TBG, and albumin. FF4 was determined with the Amerlex (Amersham International Ltd., Amersham, Bucks., U.K.), Coat-A-Count "one-step" (Diagnostic Products Corp., Los Angeles, CA 90064), Gammacoat "onestep" (Clinical Assays, Div. of Travenol Laboratories Inc., Cambridge, MA 02139), and Immophase "single-step" (Corning Medical and Scientific, Corning Glass Works, Medfield, MA 02052) FF4 RIA kits. T4 was measured with the Amerlex RIA kit and T3 uptake with the "MAA" kit (Amersham International).
TBG was determined with the Immophase RIA test system (Corning). Serum albumin was measured colorimetrically with bromcresol green. T3 uptake was expressed as the ratio of percent uptake in a sample to the percent uptake in a normal control serum (T3 uptake ratio). The FF4 index was computed by multiplying T4 by the T3 uptake ratio.
In all four FF4 assays studied, FF4 in serum and 125J labeled T4-analog tracer-designed to bind to high-affinity antisera but not to proteins that bind thyroid hormonecompete for binding to a limited quantity of antiserum to T4. At equilibrium, the proportion of tracer bound to the antisera is inversely proportional to the free hormone concentration in the sample.
The total fraction of T4 extracted by antisera in an analog assay for FF4 was determined similarly to that previously described for analog assays for FF3 (11).
Patients
To assess the thyroid status of the subjects, I determined the FF4 index, then measured serum thyrotropin or used a thyroliberin (thyrotropin-releasing factor) test where appropriate. Subjects were then classified according to biochemical and clinical findings as follows:
Euthyroid controls. Twenty-seven biochemically and clinically euthryoid women.
Pregnant subjects. Twenty women in each trimester of pregnancy, the gestational ages in the three groups being <12 weeks, 15 to 24 weeks, and 30 to 39 weeks.
Albumin-deficient subjects. Table 1 shows the mean values for TBG, albumin, total T4, and FF4 index, and results for four FF4 analog kits in six clinical groups.
Results and Discussion
The mean albumin concentrations in the third-trimester pregnancies, NT!, and albumin-deficient groups were significantly lower than control values (p <0.001) by a similar degree (74%, 65%, and 62% of the respective nonpregnant normal means). In addition, FF4 concentrations by each kit were significantly lower than normal (p <0.00 1) in thirdtrimester pregnancy and NTI. In the albumin-deficient group, Gammacoat and Immophase FF4 results were significantly lower than the control (p <0.01 and p <0.05, respectively), but Ainerlex and Coat-A-Count FF4 values were not significantly different from normal.
From these findings, therefore, it is unlikely that low Amerlex and Coat-A-Count results for FF4 in serum of patients with pregnancy or NT! are due to the effects of albumin deficiency per Se. However, low albumin concentration may contribute to decreased Gammacoat and Iminophase FF4 values for such patients. Moreover, the effect of albumin deficiency per se on the results from the analog assays is apparently related to the limitations of specific assays and is not a characteristic of FF4 analog assays per se.
Stockigt et al. (9), who found an appreciable amount of analog-albumin interaction in two FF4 assays, concluded that the spuriously low FF4 values found in albumindeficient subjects resulted from a greater availability of analog tracer in samples from these subjects than in the standards, to which the manufacturers had added albumin in an amount equivalent to the concentration in normal serum. Furthermore, Midgley and Wilkins (12) estimated, by theoretical analysis, that about 16% of the tracer is bound to albumin in the Amerlex FF4 assay; however, they suggested that the binding potential of albumin for analog would not be large enough to disturb the availability of the tracer.
I calculated the average affinities of Amerlex, Coat-ACount, Gammacoat, and Immophase antisera for T4 to be 1. 0 x 1012, 1.7 x 1012, 1.1 x 1012, and 2.2 x 1012 L'mol, respectively, based on a Scatchard plot (13) as introduced by Berson and Yalow (14) . These values were on the order of 106 greater than the established affinity constant of albumin for T4 (15) . Therefore, in accordance with previous work (12), one could expect the very avid antisera used in these assays to attract the tracer more strongly than could be resisted by the binding strength of albumin. Thus the albumin-bound tracer would in effect be fully available for binding to antisera, except, perhaps, when variations in the affinity or capacity of T4-binding sites on albumin are large (as in familial dysalbununemic hyperthyroxinemia and analbuminemia, respectively). Therefore, it is unlikely that the interaction between tracer and albumin accounts fully for the anomalous FF4 concentrations measured in sera with a range of subnormal albumin concentrations commonly encountered during clinical practice. Also, this interaction doesn't explain why, in albumin deficiency, FF4 concentrations are low when measured by some analog assays but not by others. Thus, in my view, a completely satisfactory explanation for these anomalous results cannot be made from the data of studies reported so far. In the following argument, I present data to support an alternative mechanism for the spuriously low FF4 values in albumin-deficient subjects. 
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ProposedMechanismfor the AnomalousResultsfor FT4 in Albumin-DeficientSubjects
During the initial stage of incubation in an analog assay for FF4, the high-affinity antiserum removes part of the T4 from the serum system, which then re-equilibrates to compensate for this removal (16). The final equilibrium is between FF4, T4 bound to the binding proteins, and T4 bound to the antiserum. As by the law of mass action, changes in protein-binding concentrations will produce a redistribution of the equilibrium between free and bound T4 in serum (17) . Therefore it follows that a decreased albumin concentration may alter the distribution of T4 between the serum-binding proteins and the antiserum in an assay for FF4. J.f, as a result of this redistribution, too much T4 is extracted from the serum system by the antiserum (>5% of the total T4), the equilibrium between bound and free T4 will be significantly disturbed and the assay may yield erroneous results (16, 18, 19) . Hence I looked at the concept that decreased albumin concentrations might distort the distribution of T4 between the binding proteins and antiserum as an explanation for anomalous results for FF4 in albumin deficiency.
For this study, I measured the percentage of P4 bound to antisera at the end of the incubation period for serum samples, using I-labeled nonanalog tracer and antisera from each FF4 kit, to determine how much T4 is removed from the serum system during assay. In this experiment I measured the total fraction of T4 extracted by the antisera, of which only a small percentage (15-60%) is reported to be displaceable by T4 tracer and hence quantifiable by the assay system (20) . However, it is the total amount of T4 sampled by the antiserum, and not only that which is displaceable by T4 tracer, that the serum system must compensate for during the assay. Hence the total T4 associated with the antiserum pellet acts as the best indicator of the degree of redistribution of P4 between the binding proteins and the antiserum that results from a shift in equilibrium.
In the albumin-deficient group, I found that antisera in the Amerlex, Coat-A-Count, Gammacoat, and Immophase FF4 kits during the assay removed more T4 from the serum system (4.3 ± 0.5%, 5.6 ± 1.0%, 7.5 ± 1.5%, and 6.8 ± 1.1%, respectively) than from the control (3.5 ± 0.3%, 4.5 ± 0.4%, 6.4 ± 0.9%, and 5.6 ± 0.5%, respectively; mean ± SD, see Table 1 for n). This supports the concept that decreased albumin concentrations alter the distribution of T4 between the serum-binding proteins and antisera in analog assays. (22) , calculated that removal of 10 to 30% of the serum proteinbound T4 would be expected to cause an 11 to 33% decrease in FF4 concentration during assay.
These results imply that spuriously low FF4 values are produced when the amount of T4 removed from the serum system is great enough to disrupt its equilibrium.
Relationship between Amount of T4 Sampled by an
Antiserumand the BindingPotentialof This Antiserumfor T4
As previously indicated, the antisera studied in all four FF4 kits have a much higher avidity for T4 than that of the binding proteins for P4. Therefore, an antiserum available in sufficient amounts in the assay can take up large quantities of P4 (23). Thus I considered the possibility that the various amounts of P4 sampled by antisera in FF4 kits from different manufacturers may be a function of the binding potential (affinity constant x total concentration of antisera) of these antisera for T4. This would account for why more T4 is associated with the antiserum in some analog assays than in others. However, I found no correlation (r = 0.14, p = not significant) between the binding potentials of the antisera to T4 and the mean values for the percentage of T4 associated with the antiserum in each kit in albumin deficiency.
I conclude that the binding potential of the antiserum in a kit for FF4 is not a controlling factor in the amount of P4 sampled by the antiserum.
It is doubtful
that a low albumin concentration is the primary cause of low FF4 results in analog assays in pregnancy and NT!. In addition, the failure of analogassayed FF4 results to assess correctly the thyroid status in patients with albumin deficiency per se is not a deficiency of all analog assays but is in fact related to the limitation of specific tests, possibly because of the extent to which the integrity of the analog tracers differs among the assays.
Recent evidence (7) suggests that when the albumin binding in a sample is absent or very low, analog-assayed results are distorted because of the interaction of labeled analog with albumin.
However, my findings support an alternative mechanism for anomalous FF4 results when the albumin deficiency is less severe. I propose that albumin deficiency, at concentrations commonly encountered during clinical practice, alters the equilibrium between FF4, T4 bound to binding proteins, and P4 bound to antisera in analog assays for FF4 and that this is independent of the binding potential of the assay antisera for T4. Furthermore, anomalous results for FF4 occur when the serum equilibrium in the assay is significantly altered.
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